Trial Profile
A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Tozuleristide (Primary)
- Indications CNS cancer
- Focus Diagnostic use; Registrational
- Sponsors Blaze Bioscience
- 07 Nov 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 20 Jul 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Aug 2022.